Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dexcom Glucose Test System Approved For 2-Year-Olds

Executive Summary

US FDA has heeded the advice of a July advisory committee that overwhelmingly supported expanding Dexcom's G5 Continuous Glucose Monitoring System for patients 2 and older. The company says the expanded indication will have a huge transformational effect on how patients with diabetes are treated and how such products are reimbursed.

You may also be interested in...



Market Intel: Advent Of Artificial Pancreas Tech To Galvanize Fast-Growing Diabetes Market

The global diabetes management devices market is expected to exceed $11.2bn by 2020, driven largely by the rising diabetes epidemic. This, in turn, is fueling significant innovation such as next-generation, automated artificial pancreas systems and miniaturized, less-invasive wireless technologies that can continuously track and analyze glucose levels in real-time. This feature looks more closely at these and other potentially groundbreaking new technologies, as well as the competitive landscape of the two major product segments – insulin pumps and blood glucose monitors.

Dexcom First To CGM Reimbursement Finish Line

Following a recent approval for their G5 continuous glucose monitor for use in children and adults without a finger stick, Dexcom has scored big with a new US Centers for Medicaid and Medicare Services policy that would make their CGM the first of its kind eligible for reimbursement from the agency.

Medtronic Artificial Pancreas Trial Results Published

Medtronic’s Hybrid closed-loop system is safe and improves some key patient outcomes, according to results published in the Journal of the American Medical Association. The system is currently before FDA for review.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT104234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel